1,3-Propanediol

1,3-Propanediol

SCHEMBL973980

O.OCCCO

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of 1,3-Propanediol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4376807-A1 A PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF SGLT2 INHIBITOR AND DPP-IV INHIBITOR Unison Pharmaceuticals Pvt. Ltd. (IN) 2024-06-05 EP claimed
WO-2023007511-A1 A PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF SGLT2 INHIBITOR AND DPP-IV INHIBITOR UNISON PHARMACEUTICALS PVT. LTD. (IN) 2023-02-02 WO claimed
WO-2021260617-A1 AN IMPROVED PROCESS FOR PREPARATION OF DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE HIKAL LIMITED (IN) 2021-12-30 WO claimed
US-11033544-B2 Low-dose triple combination formulation The George Institute for Global Health (AU) 2021-06-15 US claimed
US-20200306246-A1 LOW-DOSE TRIPLE COMBINATION FORMULATION The George Institute for Global Health (AU) 2020-10-01 US claimed
CN-102995075-B The copper electro-plating method of low internal stress 罗门哈斯电子材料有限公司 2016-12-21 CN claimed
WO-2026098996-A1 ODOR-CONTROL SUPERABSORBENT COMPRISING ACTIVATED CARBON MATERIAL HAVING A TRIMODAL PORE RADIUS DISTRIBUTION BASF SE (DE) 2026-05-15 WO disclosed
EP-4739697-A1 PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN Zaklady Farmaceutyczne Polpharma S.A. (PL) 2026-05-13 EP disclosed
EP-4514310-A1 TOPICAL COMPOSITIONS CONTAINING VITAMIN C Kenvue Brands LLC (US) 2025-03-05 EP disclosed
CN-119325368-A Topical compositions containing vitamin C 强生消费者公司 2025-01-17 CN disclosed
WO-2025008539-A1 PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN Zakłady Farmaceutyczne POLPHARMA S.A. (PL) 2025-01-09 WO disclosed
EP-4487910-A1 PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN Zaklady Farmaceutyczne Polpharma S.A. (PL) 2025-01-08 EP disclosed
WO-2024136185-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE, COMPRISING SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR AND ANGIOTENSIN Ⅱ RECEPTOR BLOCKER 주식회사 티에치팜 2024-06-27 WO disclosed
WO-2008055856-A1 PROCESS FOR PRODUCING SUPERABSORBENTS BASF SE (DE) 2008-05-15 WO disclosed
WO-2008055935-A2 SUPERABSORBENTS HAVING SUPERIOR PERMEABILITY AND CONVEYING PROPERTIES BASF SE (DE) 2008-05-15 WO disclosed
CN-100345909-C Composite dispersion and method for producing same DAICEL DEGUSSA LTD (JP) 2007-10-31 CN disclosed
CN-1678690-A Composite dispersion and process for producing the same DAICEL DEGUSSA LTD (JP) 2005-10-05 CN disclosed
CN-1152071-C High temp. resistant polyurethane polymers �Ϻ���ͨ��ѧ 2004-06-02 CN disclosed
CN-1342177-A High temperature resistant polyurethane polymers DOW CHEMICAL CO (US) 2002-03-27 CN disclosed
WO-2000058252-A1 HIGH-PURITY 1,3-PROPANEDIOL DERIVATIVE SOLVENT, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2000-10-05 WO disclosed